DAFTAR PUSTAKA

Abdelhak, A. *et al.* (2022) 'Blood GFAP as an emerging biomarker in brain and spinal cord disorders', *Nature Reviews Neurology*, 18(3), pp. 158–172. doi: 10.1038/s41582-021-00616-3.

Albert, K. *et al.* (2021) 'Utilising induced pluripotent stem cells in neurodegenerative disease research: Focus on glia', *International Journal of Molecular Sciences*, 22(9). doi: 10.3390/ijms22094334.

Amalia, L. (2021) 'Glial Fibrillary Acidic Protein (GFAP): Neuroinflammation Biomarker in Acute Ischemic Stroke', *Journal of Inflammation Research*, 14, pp. 7501–7506. doi: 10.2147/JIR.S342097.

Armada-Moreira, A. *et al.* (2020) 'Going the Extra (Synaptic) Mile: Excitotoxicity as the Road Toward Neurodegenerative Diseases', *Frontiers in Cellular Neuroscience*, 14(April), pp. 1–27. doi: 10.3389/fncel.2020.00090.

Assay Genie. 'Human GFAP (Glial fibrillary acidic protein) ELISA Kit'.

Assay Genie. 'Human anti-NMDAR Antibody(anti-N-methyl-D-aspartic Acid receptor Antibody) ELISA Kit'.

Balgis, B., Sumardiyono, S. and Handayani, S. (2022) 'HUBUNGAN ANTARA PREVALENSI HIPERTENSI, PREVALENSI DM DENGAN PREVALENSI STROKE di INDONESIA (ANALISIS DATA RISKESDAS DAN PROFIL KESEHATAN 2018)', *Jurnal Kesehatan Masyarakat (Undip)*, 10(3), pp. 379–384. doi: 10.14710/jkm.v10i3.33243.

Budianto, P. *et al.* (2021) 'Stroke Iskemik Akut : Dasar dan Klinis', *Univesrsitas Sebelas Maret*, (January), pp. i–123.

Dagonnier, M. *et al.* (2021) 'Acute Stroke Biomarkers: Are We There Yet?', *ntiers in Neurology*, 12(February), pp. 1–16. doi: 3389/fneur.2021.619721.

F. *et al.* (2021) 'Nmda and ampa receptor autoantibodies in brain

disorders: From molecular mechanisms to clinical features', *Cells*, 10(1), pp. 1–12. doi: 10.3390/cells10010077.

Gong, X. *et al.* (2023) 'Anti-NMDAR antibodies, the blood–brain barrier, and anti-NMDAR encephalitis', *Frontiers in Neurology*, 14(8). doi: 10.3389/fneur.2023.1283511.

Hol, E. M. and Pekny, M. (2015) 'Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system', *Current Opinion in Cell Biology*, 32, pp. 121–130. doi: 10.1016/j.ceb.2015.02.004.

Huang, Y. *et al.* (2023) 'Biomarkers and the outcomes of ischemic stroke', *Frontiers in Molecular Neuroscience*, 16(June), pp. 1–11. doi: 10.3389/fnmol.2023.1171101.

Hui, C. *et al.* (2022) 'Ischemic Stroke'. *National Library of Medicine*. https://www.ncbi.nlm.nih.gov/books/NBK499997/.

Kementerian Kesehatan Republik Indonesia. (2019) 'Pedoman Nasional Pelayanan Kedokteran Tata Laksana Stroke'.

Jaeger, H. S. *et al.* (2023) 'Diagnostic performance of Glial Fibrillary Acidic Protein and Prehospital Stroke Scale for identification of stroke and stroke subtypes in an unselected patient cohort with symptom onset < 4.5 h', *Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine*, 31(1), pp. 1–11. doi: 10.1186/s13049-022-01065-7.

Janigro, D. *et al.* (2022) 'GFAP and S100B: What You Always Wanted to Know and Never Dared to Ask', *Frontiers in Neurology*, 13(March), pp. 6–8. doi: 10.3389/fneur.2022.835597.

Jauch, E. C. *et al.* (2024) 'Ischemic Stroke Guidelines'. *Medscape.* https://emedicine.medscape.com/article/1916852-workup#c8.

linska M. L. *et al.* (2013) 'Stroke Patients Develop Antibodies that React ı Components of NMDA Receptor Subunit 1 in Proportion to Lesion Size', oke, 44(8): . doi:10.1161/STROKEAHA.113.001235.

Kalajati (2020) 'Belajar Praktis Neuroanatomi', *Sintesa Book-Indonesia*, pp. 17–19.

Kim, H. *et al.* (2022) 'Glial Fibrillary Acidic Protein in Blood as a Disease Biomarker of Neuromyelitis Optica Spectrum Disorders', *Frontiers in Neurology*, 13(March), pp. 1–9. doi: 10.3389/fneur.2022.865730.

Khaku, A. S. and Tadi, P. (2023) 'Cerebrovascular Disease'. *National Library of Medicine*. https://www.ncbi.nlm.nih.gov/books/NBK430927/.

Luger, S. *et al.* (2017) 'Glial fibrillary acidic protein serum levels distinguish between intracerebral hemorrhage and cerebral ischemia in the early phase of stroke', *Clinical Chemistry*, 63(1), pp. 377–385. doi: 10.1373/clinchem.2016.263335.

Maida, C. D. *et al.* (2020) 'Neuroinflammatory mechanisms in ischemic stroke: Focus on cardioembolic stroke, background, and therapeutic approaches', *International Journal of Molecular Sciences*, 21(18), pp. 1–33. doi: 10.3390/ijms21186454.

Puspitasari V. *et al.* (2019) 'Glial Fibrillary Acidic Protein Serum Level as a Predictor of Clinical Outcome in Ischemic Stroke', M*acedonian Journal of Medical Sciences,* 7(9), pp. 1471–1474. doi: 10.3889/oamjms.

Qin, C. *et al.* (2022) 'Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions', *Signal Transduction and Targeted Therapy*, 7(1). doi: 10.1038/s41392-022-01064-1.

Sirait G.S. (2022) 'Karakteristik Pasien Stroke Iskemik dengan Atrial Fibrilasi di RSUD Raden Mattaher Jambi Periode 2016 – 2021'. *Repository Iniversitas Jambi*. https://repository.unja.ac.id/43895/4/BAB%20I.pdf.

Soda, T. *et al.* (2023) 'The Emerging Role of N-Methyl-D-Aspartate (NMDA) ceptors in the Cardiovascular System: Physiological Implications, hological Consequences, and Therapeutic Perspectives', *International rnal of Molecular Sciences*, 24(4). doi: 10.3390/ijms24043914.

Sperber, P. S. *et al.* (2019) 'Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B)', *Stroke*, 50(11), pp. 3213–3219. doi: 10.1161/STROKEAHA.119.026100.

Sperber, P. S. *et al.* (2022) 'Serum anti-NMDA-receptor antibodies and cognitive function after ischemic stroke (PROSCIS-B)', *Journal of Neurology*, 269(10), pp. 5521–5530. doi: 10.1007/s00415-022-11203-x.

Sperber, P. S. *et al.* (2023) 'Depressive symptoms and anti-N-methyl-D-aspartate-receptor GluN1 antibody seropositivity in the PROSpective cohort with incident stroke', *Brain, Behavior, and Immunity - Health*, 34(November), p. 100705. doi: 10.1016/j.bbih.2023.100705.

Stanca, D. M. *et al.* (2015) 'GFAP and antibodies against NMDA receptor subunit NR2 as biomarkers for acute cerebrovascular diseases', *Journal of Cellular and Molecular Medicine*, 19(9), pp. 2253–2261. doi: 10.1111/jcmm.12614.

Tadi, P. and Lui, F. (2023) 'Acute Stroke'. *National Library of Medicine*. https://www.ncbi.nlm.nih.gov/books/NBK535369/.

Unnithan, A. K. A. *et al.* (2023) 'Hemorrhagic Stroke'. *National Library of Medicine*. https://www.ncbi.nlm.nih.gov/books/NBK559173/.

Wu, Q. J. and Tymianski, M. (2018) 'Targeting nmda receptors in stroke: New hope in neuroprotection Tim Bliss', *Molecular Brain*, 11(1), pp. 1–14. doi: 10.1186/s13041-018-0357-8.

Xu, Y. *et al.* (2022) 'Nanomedicine: An Emerging Novel Therapeutic Strategy for Hemorrhagic Stroke', *International Journal of Nanomedicine*, 17, pp. 1927–1950. doi: 10.2147/IJN.S357598.

Young, D. (2020) 'The NMDA Receptor Antibody Paradox: A Possible Approach to Developing Immunotherapies Targeting the NMDA Receptor', *Frontiers in Neurology*, 11(July), pp. 1–6. doi: 10.3389/fneur.2020.00635.